E. coli strain engineering for the production of advanced biopharmaceutical products

  title={E. coli strain engineering for the production of advanced biopharmaceutical products},
  author={Tania Selas Casti{\~n}eiras and Steven Gareth Williams and Antony G Hitchcock and Daniel C Smith},
  journal={FEMS Microbiology Letters},
Since the emergence of the biopharmaceutical industry in the 1980's, Escherichia coli, has played an important role in the industrial production of recombinant proteins and plasmid DNA for therapeutic use. Currently, advanced biopharmaceutical products, including rationally designed recombinant proteins and viral-vector gene therapies, offer unprecedented promise for the long-term management, and even cure of disease. As such, E. coli remains an important production host for the… 

Figures from this paper

Current trends in biopharmaceuticals production in Escherichia coli.

A review of the contribution that this model organism has made in the production of new biotech products for human medicine will include new advancements in the E. coli expression system to meet the biotechnology industry requirements, such as novel engineered strains to glycosylate heterologous proteins, add disulphide bonds and express complex proteins.

Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development

Recently, advances have been made in the various areas of bioprocessing and are being utilized to develop effective processes for producing recombinant proteins that can be used as therapeutics, vaccines, and diagnostic reagents.

Escherichia coli as an antibody expression host for the production of diagnostic proteins: significance and expression

It appears that for good yields of recombinant antibodies, aside from appropriate gene transfer and expression, the culturing parameters are of paramount importance, mainly due to the higher cell densities that can be achieved.

Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation

This review summarizes recent research, preclinical advancements, and clinical development of E. coli-produced aglycosylated therapeutic antibodies as monoclonal, bispecific, and antibody-drug conjugates for use in autoimmune, oncology, and immuno-oncology areas.

Systems biology approach in the formulation of chemically defined media for recombinant protein overproduction

The effect of medium optimization with system-level analysis on the production of recombinant proteins in different host cells is illustrated and demonstrates some of the applications of systems biology as a powerful tool for medium development.

Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments

An updated survey of the most effective and appropriate methods of preparation of antibody fragments that exploit E. coli as an expression background is proposed and the pros and cons of the different platforms available today are reviewed.

Multimodal approaches for the improvement of the cellular folding of a recombinant iron regulatory protein in E. coli

The improvement in the specific growth rate and aconitase production during chaperone GroEL/ES co-expression is attributed to the reduction in overall cellular stress caused by the expression host's aggregation-prone recombinant protein expression.

Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies

Advances in genetic engineering have enabled improvements in vaccine design and strategies, such as recombinant subunit vaccines, have emerged, expanding the number of diseases that can be prevented, and antigen display systems such as VLPs or those designed by nanotechnology have improved the efficacy of sub unit vaccines.

Process intensification at the expression system level for the production of 1-phosphate aldolase in antibiotic-free E. coli fed-batch cultures

The third-generation expression system is antibiotic-free, autotrophy-selection based and single-plasmid and, is capable to produce FucA at similar levels compared to the original commercial expression system.



Rational engineering of Escherichia coli strains for plasmid biopharmaceutical manufacturing

Recent developments in engineering of E. coli strains for plasmid DNA production are presented, essential genes for improvement of pDNA yield and quality are highlighted, and the impact of various process strategies on gene expression in pDNA production strains are analyzed.

Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives.

This review summarizes the recent advancements that may further expand the use of the E. coli expression system to produce more complex and also glycosylated proteins for therapeutic use in the future.

Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements

The current technology used for commercial production of recombinant therapeutics in E. coli is summarized and recent advances that can potentially expand the use of this system toward more sophisticated protein therapeutics are summarized.

Recombinant protein production in bacterial hosts.

Increasing Recombinant Protein Production in E. coli by an Alternative Method to Reduce Acetate

Since the development of recombinant DNA technology, it became possible to express heterologous genes in proor eukaryotic hosts, which enabled the production of all kinds of products of which the high-added value recombinant proteins, became increasingly important and as such boosted biopharmaceutical and industrial enzyme applications.

Recombinant protein expression in Escherichia coli: advances and challenges

The different approaches for the synthesis of recombinant proteins in E. coli are reviewed and recent progress in this ever-growing field is discussed.

Evaluation of three industrial Escherichia coli strains in fed-batch cultivations during high-level SOD protein production

This study directly compared the T7-based expression hosts E. coli BL21, RV308, and HMS174, focusing on evaluating the specific attributes of these strains in relation to high-level protein production of the model protein recombinant human superoxide dismutase (SOD).

Microbial Secretion via Esetec Technology

The demand for fast, safe, and cost-efficient manufacturing solutions is triggered by increasing pressure on clinical development timelines and public healthcare systems, underlining the need for innovative expression platforms that combine high productivity, protein secretion, and rapid process development.

Advanced technologies for improved expression of recombinant proteins in bacteria: perspectives and applications

An impression of expression technologies developed in recent times for enhanced production of heterologous proteins in E. coli are provided, which are of foremost importance for diverse applications in microbiology and biopharmaceutical production.